CELU vs. MDWD, OCGN, GNFT, CGC, ACRV, PRQR, RAPT, TARA, PBYI, and NBTX
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include MediWound (MDWD), Ocugen (OCGN), Genfit (GNFT), Canopy Growth (CGC), Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), RAPT Therapeutics (RAPT), Protara Therapeutics (TARA), Puma Biotechnology (PBYI), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.
Celularity vs.
MediWound (NASDAQ:MDWD) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
MediWound has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
46.8% of MediWound shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 22.1% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
MediWound has higher earnings, but lower revenue than Celularity.
In the previous week, MediWound had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for MediWound and 2 mentions for Celularity. MediWound's average media sentiment score of 0.22 beat Celularity's score of 0.10 indicating that MediWound is being referred to more favorably in the media.
MediWound presently has a consensus target price of $31.33, suggesting a potential upside of 96.45%. Given MediWound's stronger consensus rating and higher probable upside, research analysts clearly believe MediWound is more favorable than Celularity.
Celularity has a net margin of -72.72% compared to MediWound's net margin of -142.29%. MediWound's return on equity of -82.17% beat Celularity's return on equity.
MediWound received 389 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 62.23% of users gave MediWound an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Summary
MediWound beats Celularity on 12 of the 16 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
This page (NASDAQ:CELU) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy CELU Stock Free CELU Stock Alerts